Effect of genotype and methylation of CYP2D6 on smoking behaviour

Pharmacogenetics and Genomics

Volumn 25, Issue 11, 2015, Pages 531-540

  Tiili, Emmi M ^a   Antikainen, Miia S H ^a   Mitiushkina, Natalia V ^b   Sukhovskaya, Olga A ^c,d   Imyanitov, Evgeny N ^b,e,f   Hirvonen, Ari P ^a  

^a FINNISH INSTITUTE OF OCCUPATIONAL HEALTH   (Finland)

^b N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

^c 105077 Russia   (Russian Federation)

^d ST PETERSBURG RESEARCH INSTITUTE OF PHTHISIOPULMONOLOGY   (Russian Federation)

^e SAINT PETERSBURG STATE PEDIATRIC MEDICAL UNIVERSITY   (Russian Federation)

^f NORTH WESTERN STATE MEDICAL UNIVERSITY NAMED AFTER I I MECHNIKOV   (Russian Federation)

Author keywords

Cigarette smoking; Cytochrome P450 CYP2D6; DNA methylation; Genetic variation; Nicotine dependence

Indexed keywords

CYTOCHROME P450 2D6;

ADULT; AGE; ARTICLE; CPG ISLAND; DNA METHYLATION; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; RISK ASSESSMENT; SEX; SMOKING; SMOKING HABIT; ADOLESCENT; AGED; ALLELE; ENZYMOLOGY; GENETIC EPIGENESIS; GENETIC VARIATION; GENETICS; METABOLISM; MIDDLE AGED; RISK FACTOR; TOBACCO DEPENDENCE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALLELES; CPG ISLANDS; CYTOCHROME P-450 CYP2D6; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENETIC VARIATION; GENOTYPE; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; SMOKING; TOBACCO USE DISORDER; YOUNG ADULT;

EID: 84943159137     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0000000000000166     Document Type: Article

References (33)

1. Centers for Disease C, Prevention. Vital signs: current cigarette smoking among adults aged >or =18 years-United States, 2005-2010. Morb Mortal Wkly Rep 2011; 60:1207-1212.
2. Centers for Disease C, Prevention. Vital signs: current cigarette smoking among adults aged >or=18 years-United States, 2009. Morb Mortal Wkly Rep 2010; 59: 1135-1140.
3. Fiore M. 2008 PHS Guideline Update Panel, Liaisons, and Staff. Treating tobacco use and dependence: 2008 update U.S. Public Health Service Clinical Practice Guideline executive summary. Respir Care 2008; 53:1217-1222.
4. Benowitz NL. Nicotine addiction. N Engl J Med 2010; 362:2295-2303.
5. Amos CI, Spitz MR, Cinciripini P. Chipping away at the genetics of smoking behavior. Nat Genet 2010; 42:366-368.
6. Gold AB, Lerman C. Pharmacogenetics of smoking cessation: role of nicotine target and metabolism genes. Hum Genet 2012; 131:857-876.
7. Lee KW, Pausova Z. Cigarette smoking and DNA methylation. Front Genet 2013; 4:132.
8. Dayeh TA, Olsson AH, Volkov P, Almgren P, Römg T, Ling C. Identification of CpG-SNPs associated with type 2 diabetes and differential DNA methylation in human pancreatic islets. Diabetologia 2013; 56:1036-1046.
9. Kerkel K, Spadola A, Yuan E, Kosek J, Jiang L, Hod E, et al. Genomic surveys by methylation-sensitive SNP analysis identify sequence-dependent allele-specific DNA methylation. Nat Genet 2008; 40:904-908.
10. Shoemaker R, Deng J, Wang W, Zhang K. Allele-specific methylation is prevalent and is contributed by CpG-SNPs in the human genome. Genome Res 2010; 20:883-889.
11. Wan ES, Qiu W, Baccarelli A, Carey VJ, Bacherman H, Rennard SI, et al. Cigarette smoking behaviors and time since quitting are associated with differential DNA methylation across the human genome. Hum Mol Genet 2012; 21:3073-3082.
12. Turek-Plewa J, Jagodzinski PP. The role of mammalian DNA methyltransferases in the regulation of gene expression. Cell Mol Biol Lett 2005; 10:631-647.
13. Satta R, Maloku E, Zhubi A, Pibiri F, Hajos M, Costa E, Guidotti A. Nicotine decreases DNA methyltransferase 1 expression and glutamic acid decarboxylase 67 promoter methylation in GABAergic interneurons. Proc Natl Acad Sci USA 2008; 105:16356-16361.
14. Wang T, Chen M, Liu L, Cheng H, Yan YE, Feng YH, Wang H. Nicotine induced CpG methylation of Pax6 binding motif in StAR promoter reduces the gene expression and cortisol production. Toxicol Appl Pharmacol 2011; 257:328-337.
15. Launay JM, Del Pino M, Chironi G, Callebert J, Peoc'h K, Mégnien JL, et al. Smoking induces long-lasting effects through a monoamine-oxidase epigenetic regulation. PLoS One 2009; 4:e7959.
16. Gold AB, Lerman C. Pharmacogenetics of smoking cessation: role of nicotine target and metabolism genes. Hum Genet 2012; 131:857-876.
17. Yamazaki H, Inoue K, Hashimoto M, Shimada T. Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol 1999; 73:65-70.
18. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 2007; 116:496-526.
19. Hughes JR, Stead LF, Hartmann-Boyce J, Cahill K, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2014; 1:CD000031.
20. Hodgson K, Tansey K, Dernovsek MZ, Hauser J, Henigsberg N, Maier W, et al. Genetic differences in cytochrome P450 enzymes and antidepressant treatment response. J Psychopharmacol 2014; 28:133-141.
21. Kotlyar M, Brauer LH, Tracy TS, Hatsukami DK, Harris J, Bronars CA, Adson DE. Inhibition of CYP2D6 activity by bupropion. J Clin Psychopharmacol 2005; 25:226-229.
22. Caporaso NE, Lerman C, Audrain J, Boyd NR, Main D, Issaq HJ, et al. Nicotine metabolism and CYP2D6 phenotype in smokers. Cancer Epidemiol Biomarkers Prev 2001; 10:261-263.
23. Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 2004; 369:23-37.
24. Saarikoski ST, Sata F, Husgafvel-Pursiainen K, Rautalahti M, Haukka J, Impivaara O, et al. CYP2D6 ultrarapid metabolizer genotype as a potential modifier of smoking behaviour. Pharmacogenetics 2000; 10:5-10.
25. Hiroi T, Imaoka S, Funae Y. Dopamine formation from tyramine by CYP2D6. Biochem Biophys Res Commun 1998; 249:838-843.
26. Miksys S, Tyndale RF. Cytochrome P450-mediated drug metabolism in the brain. J Psychiatry Neurosci 2013; 38:152-163.
27. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict 1991; 86:1119-1127.
28. Müllenbach R, Lagoda PJ, Welter C. An efficient salt-chloroform extraction of DNA from blood and tissues. Trends Genet 1989; 5:391.
29. Bernard S, Neville KA, Nguyen AT, Flockhart DA. Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications. Oncologist 2006; 11:126-135.
30. Gaedigk A, Bhathena A, Ndjountché L, Pearce RE, Abdel-Rahman SM, Alander SW, et al. Identification and characterization of novel sequence variations in the cytochrome P4502D6 (CYP2D6) gene in African Americans. Pharmacogenomics J 2005; 5:173-182.
31. Eriksson S, Berg LM, Wadelius M, Alderborn A. Cytochrome p450 genotyping by multiplexed real-time DNA sequencing with pyrosequencing technology. Assay Drug Dev Technol 2002; 1 (Pt 1):49-59.
32. Boks MP, Derks EM, Weisenberger DJ, Strengman E, Janson E, Sommer IE, et al. The relationship of DNA methylation with age, gender and genotype in twins and healthy controls. PLoS One 2009; 4:e6767.
33. Tobacco, Genetics C. Genome-wide meta-analyses identify multiple loci associated with smoking behavior. Nat Genet 2010; 42:441-447.